Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
US10213401B2 · kind B2 · utility
15Cited by
24References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 12, 2018 |
| Grant date | Feb 26, 2019 |
| Priority date | — |
| Expiry date | Jul 12, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/999
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.